Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome

C. M. Foster, F. Comite, O. H. Pescovitz, J. L. Ross, Donald (Lynn) Loriaux, G. B. Cutler

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Six girls with McCune-Albright syndrome were treated for at least 2 months with the long-acting LHRH agonist D-Trp6-Pro9-NEt-LHRH, which previously was found to be an effective treatment for true precocious puberty. Nocturnal and LHRH-stimulated serum gonadotropin levels and plasma estradiol levels were measured before treatment and after 2-3 months of treatment. Five of the six girls had no decrease in serum gonadotropin or plasma estradiol levels during therapy, and their pubertal signs were unaffected by treatment. All five of these girls had serum gonadotropin levels that were within or below the normal prepubertal range. The sixth girl, who had gonadotropin levels in the normal pubertal range before treatment, had decreased serum gonadotropin and plasma estradiol levels during 1 yr of LHRH analog therapy. This was associated with cessation of menses and regression of secondary sexual changes. The failure of LHRH analog to modify the course of precocious puberty in the five patients with prepubertal serum gonadotropin concentrations is further evidence that the mechanism of precocious puberty in most girls with McCune-Albright syndrome differs from that in patients with true precocious puberty.

Original languageEnglish (US)
Pages (from-to)801-805
Number of pages5
JournalJournal of Clinical Endocrinology and Metabolism
Volume59
Issue number4
StatePublished - 1984
Externally publishedYes

Fingerprint

Polyostotic Fibrous Dysplasia
Gonadotropins
Gonadotropin-Releasing Hormone
Precocious Puberty
Estradiol
Serum
Plasmas
Therapeutics
Reference Values
Menstruation

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome. / Foster, C. M.; Comite, F.; Pescovitz, O. H.; Ross, J. L.; Loriaux, Donald (Lynn); Cutler, G. B.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 59, No. 4, 1984, p. 801-805.

Research output: Contribution to journalArticle

@article{446df254449640d5a9ddbf3ae8c8e345,
title = "Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome",
abstract = "Six girls with McCune-Albright syndrome were treated for at least 2 months with the long-acting LHRH agonist D-Trp6-Pro9-NEt-LHRH, which previously was found to be an effective treatment for true precocious puberty. Nocturnal and LHRH-stimulated serum gonadotropin levels and plasma estradiol levels were measured before treatment and after 2-3 months of treatment. Five of the six girls had no decrease in serum gonadotropin or plasma estradiol levels during therapy, and their pubertal signs were unaffected by treatment. All five of these girls had serum gonadotropin levels that were within or below the normal prepubertal range. The sixth girl, who had gonadotropin levels in the normal pubertal range before treatment, had decreased serum gonadotropin and plasma estradiol levels during 1 yr of LHRH analog therapy. This was associated with cessation of menses and regression of secondary sexual changes. The failure of LHRH analog to modify the course of precocious puberty in the five patients with prepubertal serum gonadotropin concentrations is further evidence that the mechanism of precocious puberty in most girls with McCune-Albright syndrome differs from that in patients with true precocious puberty.",
author = "Foster, {C. M.} and F. Comite and Pescovitz, {O. H.} and Ross, {J. L.} and Loriaux, {Donald (Lynn)} and Cutler, {G. B.}",
year = "1984",
language = "English (US)",
volume = "59",
pages = "801--805",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome

AU - Foster, C. M.

AU - Comite, F.

AU - Pescovitz, O. H.

AU - Ross, J. L.

AU - Loriaux, Donald (Lynn)

AU - Cutler, G. B.

PY - 1984

Y1 - 1984

N2 - Six girls with McCune-Albright syndrome were treated for at least 2 months with the long-acting LHRH agonist D-Trp6-Pro9-NEt-LHRH, which previously was found to be an effective treatment for true precocious puberty. Nocturnal and LHRH-stimulated serum gonadotropin levels and plasma estradiol levels were measured before treatment and after 2-3 months of treatment. Five of the six girls had no decrease in serum gonadotropin or plasma estradiol levels during therapy, and their pubertal signs were unaffected by treatment. All five of these girls had serum gonadotropin levels that were within or below the normal prepubertal range. The sixth girl, who had gonadotropin levels in the normal pubertal range before treatment, had decreased serum gonadotropin and plasma estradiol levels during 1 yr of LHRH analog therapy. This was associated with cessation of menses and regression of secondary sexual changes. The failure of LHRH analog to modify the course of precocious puberty in the five patients with prepubertal serum gonadotropin concentrations is further evidence that the mechanism of precocious puberty in most girls with McCune-Albright syndrome differs from that in patients with true precocious puberty.

AB - Six girls with McCune-Albright syndrome were treated for at least 2 months with the long-acting LHRH agonist D-Trp6-Pro9-NEt-LHRH, which previously was found to be an effective treatment for true precocious puberty. Nocturnal and LHRH-stimulated serum gonadotropin levels and plasma estradiol levels were measured before treatment and after 2-3 months of treatment. Five of the six girls had no decrease in serum gonadotropin or plasma estradiol levels during therapy, and their pubertal signs were unaffected by treatment. All five of these girls had serum gonadotropin levels that were within or below the normal prepubertal range. The sixth girl, who had gonadotropin levels in the normal pubertal range before treatment, had decreased serum gonadotropin and plasma estradiol levels during 1 yr of LHRH analog therapy. This was associated with cessation of menses and regression of secondary sexual changes. The failure of LHRH analog to modify the course of precocious puberty in the five patients with prepubertal serum gonadotropin concentrations is further evidence that the mechanism of precocious puberty in most girls with McCune-Albright syndrome differs from that in patients with true precocious puberty.

UR - http://www.scopus.com/inward/record.url?scp=0021170022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021170022&partnerID=8YFLogxK

M3 - Article

C2 - 6434582

AN - SCOPUS:0021170022

VL - 59

SP - 801

EP - 805

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -